Kenneth Ndugga-Kabuye

Dr. Ken Ndugga-Kabuye is Vice President, Gene & Cell Therapy at Premier Research. A clinical geneticist by training, Dr. Ndugga-Kabuye is an expert in the management and clinical development of rare genetic diseases. He has extensive experience executing clinical studies that leverage cutting edge approaches in the treatment of hereditary disease inclusive of Synthetic Biotics, RNAi, AAV-Mediated Gene Therapy and Enzyme Replacement Therapy.

In previous roles, Dr. Ndugga-Kabuye has supported CRO and biotechnology clients in the hereditary and rare disease space. Dr. Ndugga-Kabuye received a Bachelor of Science in Microbiology, Immunology & Molecular Genetics (MIMG) from the University of California, Los Angeles (UCLA) and a medical degree from Ross University School of Medicine. Dr. Ndugga-Kabuye performed his residency and fellowship training in Medical Genetics & Genomics at the University of Washington in Seattle, WA. He is board certified in Clinical Genetics and Genomics, by the American Board of Medical Genetics and Genomics (ABMGG).